药学学报, 2015, 50(7): 814-823
引用本文:
周洁雨, 张兰, 毛世瑞. 蛋白及多肽药物干粉吸入剂研究新进展[J]. 药学学报, 2015, 50(7): 814-823.
ZHOU Jie-yu, ZHANG Lan, MAO Shi-rui. Recent progress of dry powder inhalation of proteins and peptides[J]. Acta Pharmaceutica Sinica, 2015, 50(7): 814-823.

蛋白及多肽药物干粉吸入剂研究新进展
周洁雨, 张兰, 毛世瑞
沈阳药科大学药学院, 辽宁 沈阳 110016
摘要:
为成功设计蛋白及多肽类药物物理混合型干粉吸入剂提供理论和实践依据, 本文综述和阐明了干粉吸入剂常用载体, 药物微粉化制备技术, 影响干粉吸入剂肺部沉积的处方工艺因素, 包括载体性质、药物载体比例、混合顺序、混合方法和混合时间、药物载体相互作用, 以及粉体学性质包括粒径大小和形态、密度、粉体流动性、带电性、分散性、吸湿性对肺部沉积率的影响。依据上述讨论和粉末分散的机制, 提出了增加干粉吸入剂肺部沉积率的策略, 包括加入载体细粉、加入黏附力控制物质和对药物微粉再加工等。因此, 设计肺部沉积率高的蛋白及多肽药物的物理混合型干粉吸入剂需系统地研究药物与载体相互作用, 阐明处方工艺及粉体学性质的影响。
关键词:    蛋白质及多肽类药物      干粉吸入剂      载体      肺部沉积率     
Recent progress of dry powder inhalation of proteins and peptides
ZHOU Jie-yu, ZHANG Lan, MAO Shi-rui
School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
Abstract:
To provide theoretical and practical basis for the successful formulation design of physically-mixed inhalation dry powder of proteins and peptides, related references were collected, analyzed and summarized. In this review drug micronization technology and commonly used carriers for inhalation dry powder preparation were introduced. For proteins and peptides, supercritical fluid technology and spray-drying are more suitable because of their capabilities of keeping drug activity. Being approved by U. S. Food and Drug Administration, lactose has been extensively used as carriers in many inhalation products. Formulation and process factors influencing drug deposition in the lung, including carrier properties, drug-carrier ratio, blending order, mixing methods, mixing time and the interaction between drug and carrier, were elucidated. The size, shape and surface properties of carries all influence the interaction between drug and carrier. Besides, influence of micromeritic properties of the dry powder, such as particle size, shape, density, flowability, charge, dispersibility and hygroscopicity, on drug deposition in the lung was elaborated. Among these particle size plays the most crucial role in particle deposition in the lung. Moreover, based on the mechanisms of powder dispersity, some strategies to improve drug lung deposition were put forward, such as adding carrier fines, adding adhesive-controlling materials and reprocessing micronized drug. In order to design physically-mixed inhalation dry powder for proteins and peptides with high lung deposition, it is essential to study drug-carriers interactions systematically and illustrate the potential influence of formulation, process parameters and micromeritic properties of the powder.
Key words:    protein and peptide    dry powder inhalation    carrier    lung deposition   
收稿日期: 2015-03-13
通讯作者: 毛世瑞
Email: maoshirui@vip.sina.com
相关功能
PDF(366KB) Free
打印本文
0
作者相关文章
周洁雨  在本刊中的所有文章
张兰  在本刊中的所有文章
毛世瑞  在本刊中的所有文章

参考文献:
[1] Chen XM. New advances of pulmonay drug delivey [J]. Chin J Mod Drug App (中国现代药物应用), 2010, 4: 224-226.
[2] Agu RU, Ugwoke MI, Armand M, et al. The lung as a route for systemic delivery of therapeutic proteins and peptides [J]. Respir Res, 2001, 2: 198-209.
[3] Guilleminault L, Azzopardi N, Arnoult C, et al. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system [J]. J Control Release, 2014, 196: 344-354.
[4] Kobayashi S, Kondo S, Juni K. Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats [J]. Pharm Res, 1996, 13: 80-83.
[5] Tang Y, Zhu JB, Chen XJ. A novel pulmonary delivery system — dry powder inhalers [J]. Acta Pharm Sin (药学学报), 2009, 44: 571-574.
[6] Balducci AG, Cagnani S, Sonvico F, et al. Pure insulin highly respirable powders for inhalation [J]. Eur J Pharm Sci, 2014, 51: 110-117.
[7] Razavi Rohani SS, Abnous K, Tafaghodi M. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients [J]. Int J Pharm, 2014, 465: 464-478.
[8] Tawfeek HM, Evans AR, Iftikhar A, et al. Dry powder inhalation of macromolecules using novel PEG-co-polyester microparticle carriers [J]. Int J Pharm, 2013, 441: 611-619.
[9] Kunda NK, Alfagih IM, Dennison SR, et al. Bovine serum albumin adsorbed PGA-co-PDL nanocarriers for vaccine delivery via dry powder inhalation [J]. Pharm Res, 2015, 32: 1341-1353.
[10] Conole D, Keating GM. Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic pseudomonas aeruginosa infection in patients with cystic fibrosis [J]. Drugs, 2014, 74: 377-387.
[11] Shi N, Wu JH. Progress of dry powder inhalers [J]. Chin J New Drugs (中国新药杂志), 2007, 16: 922-925.
[12] Minne A, Boireau H, Horta MJ, et al. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients [J]. Eur J Pharm Biopharm, 2008, 70: 839-844.
[13] Healy AM, Amaro MI, Paluch KJ, et al. Dry powders for oral inhalation free of lactose carrier particles [J]. Adv Drug Deliv Rev, 2014, 75: 32-52.
[14] Elversson J, Millqvist-Fureby A, Alderborn G, et al. Droplet and particle size relationship and shell thickness of inhalable lactose particles during spray drying [J]. J Pharm Sci, 2003, 92: 900-910.
[15] Bosquillon C, Lombry C, Préat V, et al. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance [J]. J Control Release, 2001, 70: 329-339.
[16] Amidi M, Pellikaan HC, De Boer AH, et al. Preparation and physicochemical characterization of supercritically dried insulin-loaded microparticles for pulmonary delivery [J]. Eur J Pharm Biopharm, 2008, 68: 191-200.
[17] Wang HM, Fu TM, Guo LW. The influence of spray drying process conditions on physical, chemical properties and lung inhaling performance of Panax notoginseng saponins-tanshinone ⅡA composite particles [J]. Acta Pharm Sin (药学学报), 2013, 48: 925-932.
[18] Du Z, Guan YX, Yao SJ, et al. Supercritical fluid assisted atomization introduced by an enhanced mixer for micronization of lysozyme: particle morphology, size and protein stability [J]. Int J Pharm, 2011, 421: 258-268.
[19] Xu M, Wei JY, Yu BD. Advances of granulation technology in dry powder inhaler [J]. Mod Chin Med (中国现代中药), 2012, 14: 41-44.
[20] Rasenack N, Steckel H, Müller BW. Micronization of anti-inflammatory drugs for pulmonary delivery by a controlled crystallization process [J]. J Pharm Sci, 2003, 92: 35-44.
[21] Ruch F, Matijević E. Preparation of micrometer size budesonide particles by precipitation [J]. J Colloid Interface Sci, 2000, 229: 207-211.
[22] Ógáin ON, Li JH, Tajber L, et al. Particle engineering of materials for oral inhalation by dry powder inhalers. I-particles of sugar excipients (trehalose and raffinose) for protein delivery [J]. Int J Pharm, 2011, 405: 23-35.
[23] Zhou Q, Morton DAV. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces [J]. Adv Drug Deliv Rev, 2012, 64: 275-284.
[24] Wang XB, Xi RG, Yang XB, et al. Influence of formulation excipients and physical characteristics on lung deposition of dry powder inhalations [J]. Chin J New Drugs (中国新药杂志), 2010, 19: 580-583.
[25] Johnson KA. Preparation of peptide and protein powders for inhalation [J]. Adv Drug Deliv Rev, 1997, 26: 3-15.
[26] Pilcer G, Wauthoz N, Amighi K. Lactose characteristics and the generation of the aerosol [J]. Adv Drug Deliv Rev, 2012, 64: 233-256.
[27] Trainia D, Young PM, Jones M, et al. Comparative study of erythritol and lactose monohydrate as carriers for inhalation: atomic force microscopy and in vitro correlation [J]. Eur J Pharm Sci, 2006, 27: 243-251.
[28] Endo K, Amikawa S, Matsumoto A, et al. Erythritol-based dry powder of glucagon for pulmonary administration [J]. Int J Pharm, 2005, 290: 63-71.
[29] Cleland JL, Daugherty A, Mrsny R. Emerging protein delivery methods [J]. Curr Opin Biotechnol, 2001, 12: 212-219.
[30] Momin MN, Hedayati A, Nokhodchi A. Investigation into alternative sugars as potential carriers for dry powder formulation of budesonide [J]. Bioimpacts, 2011, 1: 105-111.
[31] Kaialy W, Momin MN, Ticehurst MD, et al. Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler [J]. Colloids Surf B Biointerfaces, 2010, 79: 345-356.
[32] Shadbad MRS, Millen L, Momin M, et al. The effect of solvent treatment on the performance of various carriers in dry powder inhalations containing salbutamol sulphate [J]. Iran J Basic Med Sci, 2013, 16: 873-876.
[33] Kaialy W, Larhrib H, Martin GP, et al. The effect of engineered mannitol-lactose mixture on dry powder inhaler performance [J]. Pharm Res, 2012, 29: 2139-2156.
[34] Singh DJ, Jain RR, Soni PS, et al. Preparation and evaluation of surface modified lactose particles for improved performance of fluticasone propionate dry powder inhaler [J]. J Aerosol Med Pulm Drug Deliv, 2014, doi: 10.1089/jamp.2014.1146.
[35] Du P, Du J, Smyth HDC. Evaluation of granulated lactose as a carrier for DPI formulations 1: effect of granule size [J]. AAPS PharmSciTech, 2014, 15: 1417-1428.
[36] Tee SK, Zeng XM, Martin GP, et al. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate [J]. Int J Pharm, 2000, 208: 111-123.
[37] Kaialy W, Nokhodchi A. Engineered mannitol ternary additives improve dispersion of lactose-salbutamol sulphate dry powder inhalations [J]. AAPS J, 2013, 15: 728-743.
[38] Grasmeijer F, Lexmond AJ, Van Den Noort M, et al. New mechanisms to explain the effects of added lactose fines on the dispersion performance of adhesive mixtures for inhalation [J]. PLoS One, 2014, 9: e87825.
[39] Zeng XM, Martin GP, Tee SK, et al. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation [J]. Int J Pharm, 1999, 182: 133-144.
[40] Jones MD, Price R. The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations [J]. Pharm Res, 2006, 23: 1665-1674.
[41] Cordts E, Steckel H. Capabilities and limitations of using powder rheology and permeability to predict dry powder inhaler performance [J]. Eur J Pharm Biopharm, 2012, 82: 417-423.
[42] Young PM, Chan HK, Chiou H, et al. The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance [J]. J Pharm Sci, 2007, 96: 1331-1341.
[43] Louey MD, Razia S, Stewart PJ. Influence of physico-chemical carrier properties on the in vitro aerosol deposition from interactive mixtures [J]. Int J Pharm, 2003, 252: 87-98.
[44] Young PM, Edge S, Traini D, et al. The influence of dose on the performance of dry powder inhalation systems [J]. Int J Pharm, 2005, 296: 26-33.
[45] Jones MD, Santo JGF, Yakub B, et al. The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance [J]. Int J Pharm, 2010, 391: 137-147.
[46] Lucas P, Anderson K, Staniforth JN. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers [J]. Pharm Res, 1998, 15: 562-569.
[47] Alway B, Sangchantra R, Stewart PJ. Modelling the dissolution of diazepam in lactose interactive mixtures [J]. Int J Pharm, 1996, 130: 213-224.
[48] Louey MD, Stewart PJ. Particle interactions involved in aerosol dispersion of ternary interactive mixtures [J]. Pharm Res, 2002, 19: 1524-1531.
[49] Handoko A, Ian L, Peter SJ. Influence of the polydispersity of the added fine lactose on the dispersion of salmeterol xinafoate from mixtures for inhalation [J]. Eur J Pharm Sci, 2009, 36: 265-274.
[50] Dickhoff BHJ, De Boer AH, Lambregts D, et al. The effect of carrier surface treatment on drug particle detachment from crystalline carriers in adhesive mixtures for inhalation [J]. Int J Pharm, 2006, 327: 17-25.
[51] Young PM, Cocconi D, Colombo P, et al. Characterization of a surface modified dry powder inhalation carrier prepared by "particle smoothing" [J]. J Pharm Pharmacol, 2002, 54: 1339-1344.
[52] Hooton JC, Jones MD, Price R. Predicting the behavior of novel sugar carriers for dry powder inhaler formulations via the use of a cohesive-adhesive force balance approach [J]. J Pharm Sci, 2006, 95: 1288-1297.
[53] Lohrmann M, Kappl M, Butt HJ, et al. Adhesion forces in interactive mixtures for dry powder inhalers -evaluation of a new measuring method [J]. Eur J Pharm Biopharm, 2007, 67: 579-586.
[54] Le VNP, Bierend H, Robins E, et al. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate [J]. Int J Pharm, 2012, 422: 75-82.
[55] Hinds WC. Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles [M]. New York: Wiley-Interscience, 1982.
[56] Dhand C, Prabhakaran MP, Beuerman RW, et al. Role of size of drug delivery carriers for pulmonary and intravenous administration with emphasis on cancer therapeutics and lung-targeted drug delivery [J]. RSC Adv, 2014, 4: 32673-32689.
[57] Vanbever R, Mintzes JD, Wang J, et al. Formulation and physical characterization of large porous particles for inhalation [J]. Pharm Res, 1999, 16: 1735-1742.
[58] Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large porous inhaled particles [J]. J Appl Physiol, 1998, 85: 379-385.
[59] Naini V, Byron PR, Phillips EM. Physicochemical stability of crystalline sugars and their spray-dried forms: dependence upon relative humidity and suitability for use in powder inhalers [J]. Drug Dev Ind Pharm, 1998, 24: 895-909.
[60] Service RF. Drug delivery takes a deep breath [J]. Science, 1997, 277: 1199-1200.
[61] Karhu M, Kuikka J, Kauppinen T, et al. Pulmonary deposition of lactose carriers used in inhalation powders [J]. Int J Pharm, 2000, 1996: 95-103.
[62] Thalberg K, Berg E, Fransson M. Modeling dispersion of dry powders for inhalation. The concepts of total fines, cohesive energy and interaction parameters [J]. Int J Pharm, 2012, 427: 224-233.
[63] Grasmeijer F, Frijlink HW, De Boer AH. A proposed definition of the ‘activity’ of surface sites on lactose carriers for dry powder inhalation [J]. Eur J Pharm Sci, 2014, 56: 102-104.
[64] Zhu J, Zhang H. Fluidization additives to fine powders: US, 0009340A1 [P]. 2004-01-15.
[65] Depreter F, Pilcer G, Amighi K. Inhaled proteins: challenges and perspectives [J]. Int J Pharm, 2013, 447: 251-280.
[66] Rabbani NR, Seville PC. The influence of formulation components on the aerosolization properties of spray-dried powders [J]. J Control Release, 2005, 110: 130-140.
[67] Cao W, Chen Y, Zhang ZH. Application of lactose in dry powder inhaler [J]. Chin J Mod Appl Pharm (中国现代应用药学), 2012, 29: 591-596.
[68] Islam N, Stewart P, Larson I, et al. Lactose surface modification by decantation: are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures? [J]. Pharm Res, 2004, 21: 492-499.
[69] Elbary AA, El-Laithy HM, Tadros MI. Promising ternary dry powder inhaler formulations of cromolyn sodium: formulation and in vitro-in vivo evaluation [J]. Arch Pharm Res, 2007, 30: 785-792.